HC Wainwright Reaffirms Buy Rating for Entera Bio (NASDAQ:ENTX)

HC Wainwright reiterated their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock.

Entera Bio Stock Performance

ENTX stock opened at $1.67 on Monday. The company’s 50-day moving average price is $1.86 and its 200 day moving average price is $1.92. Entera Bio has a 52 week low of $0.52 and a 52 week high of $3.35. The company has a market cap of $59.76 million, a P/E ratio of -6.42 and a beta of 1.58.

Hedge Funds Weigh In On Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Signature Estate & Investment Advisors LLC purchased a new stake in Entera Bio Ltd. (NASDAQ:ENTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 47,328 shares of the company’s stock, valued at approximately $90,000. Signature Estate & Investment Advisors LLC owned approximately 0.13% of Entera Bio as of its most recent SEC filing. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.